Abstract
Immunogenic cell death (ICD) inducers are valuable chemotherapeutic agents that elicit protective immune responses against tumors. Although many ICD inducers have emerged in recent years, specific molecular targets directly associated with ICD remain relatively unexplored. Here, two Type II ICD inducers, Pt-NHC and PlatinER (Pt-ER), were validated as bona fide ICD inducers with the ability to establish immunity against colorectal cancer in vivo. Based on Pt-ER, several ICD-inducing photoactivable probes were designed to capture their potential targets. By integrating quantitative proteomics analysis with biochemical assays, we identified PTP1B as a direct target of Pt-ER that engages in ICD. Both Pt-ER and Pt-NHC were shown to directly interact with PTP1B and inhibit its enzymatic activity. The suppression of PTP1B, by either genetic knockdown or pharmacological inhibition, enhanced the immunogenicity of tumor cells by increasing surface-exposed calreticulin and phagocytosis of cancer cells. Bioinformatic analysis also revealed that PTP1B plays a role in tumor progression and immune regulation in colorectal cancer. Therefore, our study first reveals a previously unrecognized role of PTP1B in modulating ICD and highlights its potential therapeutic values in cancer chemoimmunotherapy.
© 2025 The Authors. Published by American Chemical Society
© 2025 The Authors. Published by American Chemical Society
| Original language | English |
|---|---|
| Pages (from-to) | 2660–2672 |
| Number of pages | 13 |
| Journal | Journal of the American Chemical Society |
| Volume | 148 |
| Issue number | 2 |
| Online published | 23 Dec 2025 |
| DOIs | |
| Publication status | Published - 21 Jan 2026 |
Funding
W.H.A. acknowledges financial support from the National University of Singapore and Ministry of Education, Singapore (A8002492-00-00). M.V.B. acknowledges support from the General Research Fund (GRF) (9043889).
Publisher's Copyright Statement
- This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/
RGC Funding Information
- RGC-funded
Fingerprint
Dive into the research topics of 'Organoplatinum(II) Type II Immunogenic Cell Death Inducers Target Protein Tyrosine Phosphatase 1B to Drive Immunogenicity'. Together they form a unique fingerprint.Projects
- 1 Active
-
GRF: An Unbiased Integrated Chemical Biology Approach for Target Identification of Ruthenium-based Anticancer Drug Candidates on the Edge to Clinical Application
BABAK, M. (Principal Investigator / Project Coordinator), ANG, W. H. (Co-Investigator) & CHE, C. M. (Co-Investigator)
1/09/25 → …
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver